As the critical effector of the PI3K/Akt/mTOR pathway, genetic alterations of Akt or its abnormal expression initiate tumor development and lead to resistance to chemotherapy and radiotherapy.59 Many small-molecule inhibitors of Akt have been evaluated in clinical trials,60 but none have been approved for clinical use as of July 2022. Here, AKT1 is linked to neoplasm.